Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 11
---
 foreign private issuer, we are
exempt from certain rules under the Exchange Act that would otherwise apply if we were a company incorporated in the United States, including:

| · | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted 
 in the United States, or U.S. GAAP;                                                                      |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| 6 |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective disclosure 
 of material information.                                                                                     |

In addition, our officers, directors and principal shareholders are exempt from the
reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under the Exchange
Act with respect to their purchases and sales of our Ordinary Shares. Accordingly, an investor may receive less information about us than
it would receive about a public company incorporated in the United States.

Additionally, we elect to
follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ.

Additional Information

For additional information
related to our business and operations, please refer to the reports incorporated herein by reference, including our Annual Report on Form
20-F for the year ended December 31, 2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC,
as described in the section titled “Incorporation of Certain Information by Reference.”

| 7 |

| The Offering                                                            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Depositary Shares offered by the Selling Shareholders                   |     | An aggregate of 2,486,190,000 Ordinary Shares of the Company represented by 248,619 Depositary Shares, consisting of (1) 943,580,000 Ordinary Shares represented 94,358 Depositary Shares, issuable upon the exercise of Series G Warrants, (2) 1,478,050,000 Ordinary Shares represented by 147,805 Depositary Shares, issuable upon the exercise of Series H Warrants,  and (3)  64,560,000 Ordinary Shares represented by 6,456 Depositary Shares, issuable upon the exercise of Warrant Agent Warrants, all issued